Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE 250

 544.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 913.00p
  • 52 Week Low: 424.00p
  • Currency: UK Pounds
  • Shares Issued: 121.05m
  • Volume: 433,883
  • Market Cap: £658.51m
  • RiskGrade: 125
  • Beta: 0.03

OXB Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -13.3% -8.7%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 4.1 3.5
Pr/Book 7.6  
Latest F'cast
Revenue 31.0% 15.4%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

OXB Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 142.80 19.88 22.77p 54.0 n/a n/a n/a 0.0%
31-Dec-22 139.99 (45.98) (41.29)p n/a n/a n/a n/a 0.0%
31-Dec-23 89.54 (188.53) (163.11)p n/a n/a n/a n/a 0.0%
31-Dec-24 128.80 (47.26) (41.75)p n/a n/a n/a n/a 0.0%
31-Dec-25 168.74 (31.94) (26.92)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

OXB Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 194.77 (17.04) (26.68)p n/a n/a n/a n/a 0.0%
31-Dec-27 244.73 6.30 (2.82)p n/a n/a n/a n/a 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

OXB Company Announcements

Grant of Award 02-Oct-2026 14:41 RNS
Total Voting Rights 01-Oct-2026 07:00 RNS
PDMR Dealing 28-Sep-2026 15:26 RNS

OXB ShareCast News

Director dealings: Oxford Biomedica chair ups st... 24-Sep-2026 ShareCast
Oxford Biomedica delivers solid H1 growth, recor... 22-Sep-2026 ShareCast
Deutsche Bank downgrades Oxford Biomedica after ... 18-Aug-2026 ShareCast

OXB Top Newspaper Links

Should you buy shares in Oxford Biomedica? 29-Jul-2026 Times
Need to know: Opec cuts forecast ... Tesco cuts ... 16-Aug-2008 Times
Need to know 10-May-2008 Times

Latest OXB Director Deals

Traded Action Notifier PriceAmountValue
28-Sep-26 Buy Peter Soelkner 511.24p 1,672 £8,547.91
25-Sep-26 Buy Peter Soelkner 516.92p 1,667 £8,615.29
23-Sep-26 Buy Roch Doliveux 505.00p 20,250 £102,262.50

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

OXB Market Data

Currency UK Pounds
Share Price 544.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 913.00p
52 Week Low 424.00p
Volume 433,883
Shares Issued 121.05m
Market Cap £658.51m
Beta 0.03
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
42.74% below the market average42.74% below the market average42.74% below the market average42.74% below the market average42.74% below the market average
42.11% below the sector average42.11% below the sector average42.11% below the sector average42.11% below the sector average42.11% below the sector average
Price Trend
85.50% above the market average85.50% above the market average85.50% above the market average85.50% above the market average85.50% above the market average
62.79% above the sector average62.79% above the sector average62.79% above the sector average62.79% above the sector average62.79% above the sector average
Income Not Available
Growth
46.86% above the market average46.86% above the market average46.86% above the market average46.86% above the market average46.86% above the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average

What The Brokers Say

Strong Buy 3
Buy 1
Neutral 4
Sell 0
Strong Sell 0
Total 8
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 05-Oct-2026

Time Volume / Share Price
16:35 96,141 @ 544.00p
16:35 610 @ 544.00p
16:35 239 @ 544.00p
16:35 185 @ 544.00p
16:35 379 @ 544.00p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page